News for ADOCY Stock

ADOCIA Announces the Release of its Universal Registration Document for the Year 2022 ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities ADOCIA Announces Its Annual Shareholders’ Meeting to Be Held on May 11, 2023 in Paris Number of Shares and Voting Rights of ADOCIA as of March 31st, 2023 Number of Shares and Voting Rights of ADOCIA as of February 28th, 2023 ADOCIA Announces Its Annual Results for 2022 and Provides Corporate and Financial Update Number of Shares and Voting Rights of ADOCIA as of January 31st, 2023 Adocia Publishes Its Letter to Shareholders ADOCIA Announces Half Year Report on Adocia’s Liquidity Agreement With Kepler Capital Markets Number of Shares and Voting Rights of ADOCIA as of December 31st, 2022 ADOCIA Announces its Financial Calendar for 2023 ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023 Number of shares and voting rights of ADOCIA as of November 30th, 2022 Adocia Strengthens Its Cash Position with EUR 6 Million Through the Issuance of Convertible Bonds Subscribed by European Investors in Order to Accelerate the Development of Key Products Number of Shares and Voting Rights of ADOCIA as of October 31st, 2022 ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates Number of Shares and Voting Rights of ADOCIA as of September 30th, 2022 ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis ADOCIA: Upcoming Investor Meetings ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update Adocia Will Release Its 2022 Half-year Results on September 19th and Hold a Webinar on September 20th Number of Shares and Voting Rights of ADOCIA as of August 31st, 2022 ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes Number of Shares and Voting Rights of ADOCIA as of July 31st, 2022 ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update Adocia Announces Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets Number of Shares and Voting Rights of ADOCIA as of June 30th, 2022 Adocia Publishes its Letter to Shareholders ADOCIA Announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes ADOCIA confirms its eligibility for the PEA–PME Number of shares and voting rights of ADOCIA as of May 31st, 2022 ADOCIA Announces its Annual Shareholders’ Meeting to Be Held on June 28, 2022 in Paris ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao Number of Shares and Voting Rights of ADOCIA as of April 30th, 2022 ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao ADOCIA Announces the Release of its Universal Registration Document for the Year 2021 ADOCIA Announces Its Annual Results for 2021 and Presents an Update on Activities Adocia: Number of Shares and Voting Rights of ADOCIA as of March 31st, 2022 ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao ADOCIA Strengthens Its Cash Position by 19 Million Euros Following a Real Estate Transaction Number of Shares and Voting Rights of Adocia as of February 28th, 2022 ADOCIA Announces 2021 Fourth Quarter Financial Results Number of Shares and Voting Rights of ADOCIA as of January 31st, 2021 Adocia Announces Half Year Report on Adocia’s Liquidity Agreement With Kepler Capital Markets Number of shares and voting rights of ADOCIA as of December 31st, 2021 Adocia Announces Its Financial Calendar for 2022 Number of Shares and Voting Rights of ADOCIA as of November 30th, 2021 Number of Shares and Voting Rights of ADOCIA as of November 30th, 2021 Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides Number of Shares and Voting Rights of ADOCIA as of October 31st, 2021 Adocia Announces 2021 Third Quarter Financial Results and a Financing of €7 Million Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China Number of Shares and Voting Rights of ADOCIA as of September 30th, 2021 Adocia Announces Oral Presentation Reviewing M1Pram (ADO09) at the 57th Annual Meeting of the European Association for the Study of Diabetes (EASD) Number of Shares and Voting Rights of ADOCIA as of August 31st, 2021 Adocia to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Adocia Announces First Half 2021 Financial Results and Provides an Update on Activities